• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Callisto Pharmaceuticals Receives Investment Recommendation From Independent European Stock Newsletter; Strong Buy Investor Newsletter Cites Company's Drug Development Pipeline and Clinical Progress of Atiprimod and L-Annamycin

Posted on: Tuesday, 18 April 2006, 03:03 CDT

Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced that Strong Buy Investor, an independent European online investment newsletter, last week spotlighted the Company's promising investment potential, citing its research pipeline of new anticancer drug candidates and other competitive advantages.

In its website report on Callisto, the Strong Buy Investor newsletter discussed the potential growth of shareholder value in the biotechnology sector, particularly involving companies with a promising research pipeline. "Oftentimes stock values have increased tenfold within years of a successful clinical development process, if the US FDA gives its approval at the end of the process and therefore the last obstacle for market entrance is taken," the Strong Buy report stated. "One of the companies that appear highly interesting is Callisto Pharmaceuticals."

The report specifically noted Callisto's anticancer drug candidates Atiprimod and L-Annamycin. The Company is developing Atiprimod as a treatment for multiple myeloma and carcinoid cancer. It is developing L-Annamycin for relapsed acute leukemia. Callisto also has a number of other proprietary new drug candidates in its development pipeline.

The independent Germany-based Strong Buy Investor report added: "Callisto is, with its medical candidates, substantially closer to the market than it appears at first sight."

About Strong Buy Investor

Strong Buy Investor is an online investment newsletter published in Germany by an experienced editorial team, which has been involved in the reporting of stock exchange for many years and provides extensive knowledge and excellent contacts on the market. The Strongbuy-Investor newsletter primarily addresses the speculatively oriented investor. However, the reports are written in a way every member of the stock market can profit from, independently of his previous knowledge. Its recommendations have been fundamentally investigated by a competent editorial team with years of experience. For more information visit www.strongbuy-investor.de.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for other significant health care markets, including ulcerative colitis and biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed acute leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer, and advanced carcinoid cancer. Atiprimod is presently in Phase I/IIa human clinical trials in relapsed multiple myeloma patients, and advanced cancer patients, respectively. Callisto also has drugs in preclinical development for gastrointestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect,""should,""anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K for the year ended December 31, 2005, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.

Source: Business Wire

More News in this Category